Member Info for BlueGlow

Reading the release i dont think anyone did Trek.

It reads rather ambiguously.

Have been reluctant to post anything positive as i dont want to mislead anyone when i dont know for sure myself.

Added some as a precaution. this AM.

In medicine the Indication refers to the condition the drug is designed to treat. It may be that this is part is not granted until its "label" ready for use, as a designated treatment.

lol Tro.

Have been reading up all day to try to understand the implications of designation and indication in the release. Still dont fully understand why the Indication is not specified.

Assume that comes after further testing.

3.90 to sell

On the move...

Link some may find helpful re designation and indication

https://www.pharmaceuticalcommerce.com/view/common-misconceptions-about-the-orphan-drug-designation

IQAI.

Generic Name: Gallium maltolate
Date Designated: 02/27/2023
Orphan Designation: Treatment of glioblastoma
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Sponsor: Imaging Biometrics, LLC
13416 Watertown Plank Road
Suite 260
Elm Grove, Wisconsin 53122
United States

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=924822

Requesting Orphan Designation The sponsor must submit the request for orphan designation to
OOPD before filing the NDA/BLA. If OOPD grants orphan designation, then the drug is said to have
"orphan status."

Sponsors requesting designation of the same drug for the same indication as a
previously designated product must submit their own data in support of their designation request.

Orphan drug designation qualifies sponsors for incentives including:

Tax credits for qualified clinical trials
Exemption from user fees
Potential seven years of market exclusivity after approval

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm

Touchstone begins sidetrack drilling at Royston-1X well in Trinidad

Touchstone Exploration has commenced operations at the Royston-1X sidetrack well on the onshore Ortoire Block in Trinidad and Tobago.

Royston-1X is re-entering the previously drilled Royston-1 well and is expected to be drilled to a measured depth of 11,300 feet, targeting hydrocarbon accumulations in the Middle Miocene Herrera overthrust, intermediate, and subthrust sheets.

I dont know if you still follow PRD.

GRH is back, so the board was very lively over the weekend :)

They have mud issue with the MOU2 drill, MOU1 due to be tested shortly.

May need a small raise to resolve MOU2 issues, if that occurs before MOU1 test results, it would present a good buying opp imo.

Have taken a few SOUC, just to make it more interesting.

Havent listened to the CGNR interview you posted yet, but from skim reading the board it sounds like slow progress, i sold at around 35p with the intention of getting back in, but Demir dont seem to be in a hurry to drill.

SOUC.

Agree Tro.

Just watching presently but plenty of upside when it turns.

Malcy has a 260p target.

Well done nom.

I really want to buy some.

https://www.bbc.co.uk/programmes/p0cmswzc

Link to an interview i listened to a while ago, in which Nicky Campbell speaks with a former civil servant about UFO's.

Was quite eye-opening.

Going long on BAE Systems / Lockheed Martin.

...for when they start landing!

Highlights the lack of raw materials, copper, amongst others.

Forward looking expectations for demand, etc.

https://www.youtube.com/watch?v=sgOEGKDVvsg

https://en.wikipedia.org/wiki/Eejit

To be fair, Brexit and things beginning with e.

It seems the future of the uranium mine hangs on the granting of an NSC-II license.

They applied in 2016, rebuffed in 2021, and subsequently appealed.

They reckon with an NSC-II there would be no further barrier to mine construction, other than finance. So the NSC-II is the last chance the politicians will have to block its progress.

And it sound like it was blocked on political grounds ( think PRD and their FSRU project) rather than anything technical.

So it could be a change of personnel in the relevant department, a comment in the press by someone with influence, something thats boosted the perceived likelihood of a favorable outcome? Just guessing really, could just be a TA thing.

BKY now up 11% in Madrid.